Chasing Merck, Eisai launches insomnia drug Dayvigo in JapanEisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Share XChasing Merck, Eisai launches insomnia drug Dayvigo in Japanhttps://pharmaphorum.com/news/chasing-merck-eisai-launches-insomnia-drug-dayvigo-in-japan/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Merck & Co’s Keytruda approved for second “tumour agnostic” useMerck & Co’s Keytruda cancer immunotherapy has been approved by the FDA in another “tumour agnostic” use, in Share XMerck & Co’s Keytruda approved for second “tumour agnostic” usehttps://pharmaphorum.com/news/merck-cos-keytruda-approved-for-second-tumour-agnostic-use/
Merck & Co’s Keytruda fails in first line bladder cancerMerck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Share XMerck & Co’s Keytruda fails in first line bladder cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-first-line-bladder-cancer/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Hot shots named in Trump’s Warp Speed drive for coronavirus vaccinePresident Donald Trump’s Operation Warp Speed, which aims to make a coronavirus vaccine widely available by year-end, has Share XHot shots named in Trump’s Warp Speed drive for coronavirus vaccinehttps://pharmaphorum.com/news/hot-shots-named-in-trumps-warp-speed-drive-for-coronavirus-vaccine/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
